# Resolution Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/resolution-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.resolution-tx.com
- Total disclosed funding: $134M
- Latest round: Series B (Oct 3, 2024)
- Investors on record: 1

## About

Based in London, UK, and founded by John Campbell and Stuart Forbes in 2020, Resolution Therapeutics Limited, operates as a developer of macrophage cell therapies for the treatment of chronic liver disease. In October 2024, returning investor Syncona Limited led a GBP 63.5 million in series B funding for Resolution Therapeutics Limited.

The company offers an induced pluripotent stem cell (iPSC) derived macrophage cell therapy for the treatment of inflammatory organ diseases like chronic liver disease. The company has partnered with Pancella for the manufacturing of macrophages using monocytes from the blood.

The company will use the funding to advance its lead candidate, RTX001, an engineered macrophage cell therapy for patients with end-stage liver disease.

## Funding rounds

- Series B, Oct 3, 2024, $85M — Syncona
- Series A, Apr 5, 2022, $13M — Syncona
- Series A, Dec 2, 2020, $36M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B